Colorectal cancer stage IV – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 05 Jun 2026 10:50:38 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Colorectal cancer stage IV – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Tisotumab Vedotin, Pembrolizumab, and Platinum Drug Combination for Patients with Advanced or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-of-tisotumab-vedotin-pembrolizumab-and-platinum-drug-combination-for-patients-with-advanced-or-metastatic-solid-tumors/ Wed, 29 Apr 2026 14:57:05 +0000 https://clinicaltrials.eu/trial/study-of-tisotumab-vedotin-pembrolizumab-and-platinum-drug-combination-for-patients-with-advanced-or-metastatic-solid-tumors/ This clinical trial is focused on studying the effects of a treatment called tisotumab vedotin on patients with locally advanced or metastatic solid tumors. These are types of cancers that have spread from their original location to other parts of the body. The study aims to evaluate how well tisotumab vedotin works on its own and in combination with other treatments. In some parts of the study, tisotumab vedotin is combined with pembrolizumab, a medication that helps the immune system fight cancer, and a platinum agent, which is a type of chemotherapy drug.

The study is divided into several parts. In some parts, patients will receive tisotumab vedotin alone, while in others, it will be given alongside pembrolizumab or both pembrolizumab and a platinum agent like cisplatin or carboplatin. These medications are administered through an intravenous infusion, which means they are given directly into the bloodstream through a vein. The study will observe the effects of these treatments over time to understand their impact on the cancer and any side effects that may occur.

The purpose of this study is to assess the antitumor activity of tisotumab vedotin and its combinations in treating these advanced cancers. The study will monitor how the tumors respond to the treatment, how long it takes for a response to occur, and the overall survival of the patients. This information will help determine the effectiveness and safety of the treatment options being tested.

]]> Study on Calcium Chloride Hexahydrate, Irreversible Electroporation, and Pembrolizumab for Patients with Metastatic Colorectal Cancer https://clinicaltrials.eu/trial/study-on-calcium-chloride-hexahydrate-irreversible-electroporation-and-pembrolizumab-for-patients-with-metastatic-colorectal-cancer/ Wed, 29 Apr 2026 14:25:18 +0000 https://clinicaltrials.eu/trial/study-on-calcium-chloride-hexahydrate-irreversible-electroporation-and-pembrolizumab-for-patients-with-metastatic-colorectal-cancer/ This clinical trial is focused on studying a treatment for patients with metastatic colorectal cancer, which is a type of cancer that starts in the colon or rectum and has spread to other parts of the body. The study involves a combination of treatments, including calcium electroporation and irreversible electroporation, followed by an immunotherapy drug called pembrolizumab, also known by its code name MK-3475. Calcium electroporation is a technique that uses electrical pulses to introduce calcium into cancer cells, while irreversible electroporation uses electrical pulses to destroy cancer cells. Pembrolizumab is a medication that helps the immune system fight cancer cells.

The purpose of this study is to determine how effective and safe this combination of treatments is for patients with this type of cancer. Participants in the study will receive the treatments over a period of time, with the maximum treatment period being 12 months. The study will involve regular monitoring and assessments to evaluate the response to the treatment and any side effects that may occur. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

Throughout the study, various methods will be used to assess the treatment’s impact, including biopsies, which are small samples of tissue taken from the body, and imaging techniques like ultrasound. The study aims to gather information on how the treatment affects the cancer, the overall survival of participants, and their quality of life. The results will help determine if this combination of treatments could be a beneficial option for patients with metastatic colorectal cancer.

]]> Study Comparing MK-1308A and Pembrolizumab for Patients with Advanced Colorectal Cancer with High Microsatellite Instability or Mismatch Repair Deficiency https://clinicaltrials.eu/trial/study-comparing-mk-1308a-and-pembrolizumab-for-patients-with-advanced-colorectal-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency/ Wed, 29 Apr 2026 14:23:22 +0000 https://clinicaltrials.eu/trial/study-comparing-mk-1308a-and-pembrolizumab-for-patients-with-advanced-colorectal-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency/ This clinical trial is focused on studying treatments for Stage IV Colorectal Cancer, specifically in patients with a condition known as Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR). These are specific types of genetic changes in cancer cells that can affect how the cancer grows and responds to treatment. The study will explore the effectiveness of several treatments, including a combination of drugs called MK-1308A (which includes quavonlimab and pembrolizumab), as well as other treatments like MK-4280A, MK-7684A, and MK-4830 combined with pembrolizumab. Pembrolizumab is also being tested on its own.

The purpose of the study is to compare how well these treatments work in shrinking tumors and improving patient outcomes. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will be conducted over a period of time, and participants will be monitored to see how their cancer responds to the treatment. The study will also look at how long the response lasts, how long patients live without the cancer getting worse, and overall survival rates.

Throughout the study, the safety of the treatments will be closely monitored, and any side effects will be recorded. The study aims to provide valuable information on the effectiveness of these treatments for patients with this specific type of colorectal cancer, potentially leading to better treatment options in the future.

]]>